Share Name Share Symbol Market Type Share ISIN Share Description
Iq-ai Limited LSE:IQAI London Ordinary Share JE00BD4H0R42 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.05 1.61% 3.15 3.00 3.30 3.15 3.05 3.10 890,945 14:13:33
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Retailers 0.3 -0.6 -0.5 - 4

IQ-AI Limited KFDA Clearance for StoneChecker Software

20/01/2020 7:00am

UK Regulatory (RNS & others)

Iq-ai (LSE:IQAI)
Historical Stock Chart

From Dec 2019 to Jun 2020

Click Here for more Iq-ai Charts.


RNS Number : 2389A

IQ-AI Limited

20 January 2020


("IQ-AI" or the "Company")

IQ-AI Announce Korean FDA Clearance to Market for StoneChecker Software, and GMP certification for Imaging Biometrics, and the appointment of Dr Balaji Ganeshan as consultant

IQ-AI has received notification that the Korean FDA (KFDA) has cleared StoneChecker Software for marketing in the Republic of Korea, a key market for high-tech medical imaging hardware and software. In addition, Imaging Biometrics (IB) has received GMP certification.

Trevor Brown, Chief Executive of IQ-AI commented, "We are delighted that StoneChecker Software has received KFDA approval for marketing in the Republic of Korea, our Korean distributor's marketing plans can now be fully implemented. It also gives me great pleasure to welcome back Dr Balaji Ganeshan to the team. Dr Ganeshan, an exceptionally innovative medical imaging entrepreneur and scientist, has invaluable expertise and ideas in a number of key technologies relevant to the Company. He will be working as a consultant for IB."

Dr Ganeshan, who was previously a director of StoneChecker Software, holds the position of Senior Research Associate at the Institute of Nuclear Medicine at University College London and is a prolific academic scientist in the area of medical image analysis.

Dr. Balaji Ganeshan commented, "I very much look forward to working alongside Trevor Brown again, and also the team at IB, on all the technologies that IQ-AI have access to."

The Directors of the Company accept responsibility for the contents of this announcement.


For further information, please contact:

 IQ-AI Limited 
  Trevor Brown/Michael Schmainda 
  Tel: 020 7469 0930 
 Peterhouse Capital Limited (Financial Adviser and Broker) 
  Lucy Williams/Heena Karani 
  Tel: 020 7220 9797 

About IQ-AI Ltd

IQ-AI, Ltd, the parent company of StoneChecker(R) and Imaging Biometrics(R), is focused on advanced and state of the art medical software and services. Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. Please visit for further information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

January 20, 2020 02:00 ET (07:00 GMT)

1 Year Iq-ai Chart

1 Year Iq-ai Chart

1 Month Iq-ai Chart

1 Month Iq-ai Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200604 15:03:42